In a retrospective series of 35 patients treated with neoadjuvant ADT prior to prostatectomy and 40 control patients, Gannon et al. previously showed that ADT may increase the inflammatory infiltrate in treated prostate tumours with increased numbers of CD3+, CD8+, and CD69+ cells seen [31]. This evidence concerns the gene CD8A and prostate neoplasm.